Patent ID: 7572602

Claim:
A recombinant nucleic acid encoding a fusion protein, wherein the fusion protein comprises the endolysin consisting of contiguous amino acid residues 1-443 of SEQ ID NO:2 from Group B Streptococcus B30 bacteriophage, wherein the endolysin comprises at least a D-alanyl-L-alanine endopeptidase amino terminus (CHAP) domain, and an Acm glycolase (lysozyme-like) domain, further consisting of four mutations C26S, H91A, D158A and E185A as shown in FIG. 2 , wherein the C-terminal end of the endolysin is fused in-frame to the N-terminal end of the lysostaphin consisting of contiguous amino acid residues 1-246 of SEQ ID NO:4, wherein the lysostaphin further consists of two mutations at residues 125 and 232 to glutamine as shown in FIG. 3 , wherein the fusion protein has antimicrobial activity and kills Staphylococcus aureus bacteria and Streptococcus agalactiae, dysgalactia , and uberis bacteria.